Cho KY, et al. - In this open-label, prospective, randomized, parallel-group comparison trial involving patients with type 2 diabetes mellitus (T2DM), researchers compared the effects of dapagliflozin (DAP) and pioglitazone (PIO) on body weight and glycemic control. A total of 71 patients on PIO were either switched to DAP (n = 36) at 5 mg per day or continued on PIO (n = 35). Superiority of weight loss and non-inferiority of hemoglobin A1c level after 24 weeks with DAP were the primary endpoints. Results of suggested that DAP promotes weight loss in patients with T2DM and may reduce fluid retention, thus decreasing the occurrence of cardiovascular events.